A Novel AβPP M722K Mutation Affects Amyloid-β Secretion and Tau Phosphorylation and May Cause Early-Onset Familial Alzheimer's Disease in Chinese Individuals.
Qianqian Wang, Jianping Jia, Wei Qin...
https://pubmed.ncbi.nlm.nih.gov/26402764/Actively Recruiting
Led by Capital Medical University · Updated on 2026-03-23
40000
Participants Needed
65
Research Sites
N/A
Total Duration
Researchers are establishing and continuously improving a nationwide research network focused on Familial Alzheimers Disease FAD in China. This observational study collects detailed information on family demographics, genetics, neuropsychology, neuroimaging, and biomarkers to better understand FADs genetic features, disease progression, and diagnosis and treatment status in the Chinese population. The study aims to clarify epidemiological and clinical characteristics of FAD, discover early diagnostic biomarkers, and develop a genetic counseling model. The study includes cohorts with known mutations in PSEN1, PSEN2, and APP genes, including both mutation carriers and noncarriers, presymptomatic and symptomatic individuals, as well as normal cognitive control participants. It involves comprehensive epidemiological surveys across different nationalities and regions in China, regular collection and follow-up of biological samples like blood, urine, and saliva, and data including neuropsychology and imaging. The project uses advanced imaging methods such as structural MRI and PET scans to monitor brain changes and biomarkers at different stages of Alzheimers progression. Participants will undergo regular assessments including neuropsychological tests, brain imaging, and biomarker analysis to track disease development over time. The study measures the prevalence of gene mutations and patterns of genetic, biofluid, imaging, and cognitive markers over multiple years. It also evaluates changes in brain structure, metabolism, amyloid and tau deposition, and tests non-drug interventions. The total participation duration varies, with some measures assessed yearly for up to 10 years, supporting long-term monitoring and data collection.
CONDITIONS
The Chinese Familial Alzheimer's Network
J
Jianping Jia, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Capital Medical University
Lead Sponsor
Beijing Tiantan Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 to 10 years
Participants are regularly followed over multiple years to collect biological samples and data including neuropsychology assessments and imaging, tracking changes from asymptomatic to symptomatic stages.
Annual visits for up to 10 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Qianqian Wang, Jianping Jia, Wei Qin...
https://pubmed.ncbi.nlm.nih.gov/26402764/Wenwen Li, Yana Pang, Yan Wang...
https://pubmed.ncbi.nlm.nih.gov/37365538/Heyun Yang, Tingting Hou, Wei Wang...
https://pubmed.ncbi.nlm.nih.gov/29614686/Jing Dong, Wei Qin, Cuibai Wei...
https://pubmed.ncbi.nlm.nih.gov/28269784/Qiongqiong Qiu, Luxi Shen, Longfei Jia...
https://pubmed.ncbi.nlm.nih.gov/30958370/Jianping Jia, Xiumei Zuo, Xiang-Fei Jia...
https://pubmed.ncbi.nlm.nih.gov/26256457/Wei Qin, Jianping Jia
https://pubmed.ncbi.nlm.nih.gov/18445230/Wei Wang, Lu Lu, Qiao-Qi Wu...
https://pubmed.ncbi.nlm.nih.gov/27079718/Meina Quan, Tan Zhao, Yi Tang...
https://pubmed.ncbi.nlm.nih.gov/31937364/Longfei Jia, Yue Fu, Luxi Shen...
https://pubmed.ncbi.nlm.nih.gov/31914229/Capital Medical University
Lead Sponsor
Beijing Tiantan Hospital
Collaborating Sponsor